Cited by 36Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerBioactive Compounds and Antitumor Agents

Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc

Du, Cheng, Guan, Xin, Liu, Yao, Xu, Zhuxuan, Du, Xiaowei, Li, Baolei, Wang, Meiling, Zheng, Zhendong·2022·Cancer Chemotherapy and Pharmacology

Abstract

Purpose Disulfiram (DSF) is an approved drug for the treatment of alcohol dependence. Accumulating evidence indicates that DSF, alone or in combination with copper (Cu), possesses strong antitumor activity in various malignancies. This study investigated the effects of DSF on gastric cancer (GC) and the potential mechanisms involved. Methods GC cell proliferation and apoptosis upon treatment with DSF with or without copper were analyzed using CCK-8 assay, colony formation assay, and flow cytometry. Glucose metabolism was investigated using glucose consumption and lactate production assays. The expression of caspase-3, Bcl-2, LC-3, P62, S6K1, c-Myc, GLUT1, PKM2, and LDHA was analyzed using western blot assay. In vivo nude mice studies were performed to verify the findings from in vitro analyses. Results Our study showed that DSF was highly toxic to GC cells in a Cu-dependent manner. Nontoxic concentrations of Cu enhanced the inhibitory effects of DSF on cell viability and colony formation. DSF also induced apoptotic and autophagic cell death in the presence of Cu. In addition, DSF/Cu inhibited glycolysis and xenograft growth of GC cells by suppressing the expression of S6K1, c-Myc, and their downstream molecules, including GLUT1, PKM2, and LDHA. Conclusion Our study demonstrated that DSF/Cu exerted antitumor activity against GC cells both in vitro and in vivo. DSF/Cu may represent a promising therapeutic strategy for the treatment of GC.

Integrity signals

Registry

Crossref · 10.1007/s00280-022-04398-3

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A combination of disulfiram and copper significantly reduces expression levels of S6K1, MYC, and their downstream targets GLUT1, PKM2, and LDHA.

    “Furthermore, a combination of DSF and copper was shown to significantly reduce the expression levels of key molecules, including S6K1, MYC, and their downstream targets, glucose transporter 1 (GLUT1), PKM2, and lactate dehydrogenase A (LDHA), which are integral to the regulation of critical cellular processes, such as apoptosis, cell differentiation, and metabolism.112”

    From Drug repurposing for cancer therapy (2024) · cites this paper as [112]

  • Disulfiram inhibits glycolysis of cancer cells in a copper-dependent manner.

    “For example, Du et al. found that DSF inhibited the glycolysis of cancer cells in a copper-dependent manner.”

    From Drug repurposing for cancer therapy (2024) · cites this paper as [112]

The citation lists haven’t been fetched yet

References 39 · Cited by 36

Authors
Du, C., Guan, X., Liu, Y., Xu, Z., Du, X., Li, B., Wang, M., & Zheng, Z.
Affiliations
General Hospital of Shenyang Military Region (CN)
Corresponding author
Zheng, Zhendong
Venue
Cancer Chemotherapy and Pharmacology
Published
2022-02-24
Volume
89
Issue
4
Pages
451-458
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W4214685118
Cited by
36
References
39
Citations by year
2026: 7 · 2025: 6 · 2024: 11 · 2023: 10 · 2022: 2
FWCI
3.37
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Chemotherapy and Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81702423)
  • Postdoctoral Research Foundation of China (2017M623442, 2018T111169)
  • Shenyang Science and Technology Bureau (213463)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Keywords
disulfiram, copper, gastric cancer, anticancer activity, S6K1, c-Myc, glycolysis, glucose metabolism, GLUT1, PKM2, LDHA, apoptosis, autophagy, xenograft tumor growth, drug repurposing
MeSH terms
Animals, Copper, Disulfiram, Humans, Mice, Nude, Stomach Neoplasms, Proto-Oncogene Proteins c-myc, Xenograft Model Antitumor Assays, Ribosomal Protein S6 Kinases, 70-kDa, Cell Line, Tumor, Glucose Transporter Type 1, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review